A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer
- 1 July 2001
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 37 (11) , 1366-1371
- https://doi.org/10.1016/s0959-8049(01)00117-4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinomaCancer, 2000
- Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancerAnnals of Oncology, 2000
- Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group studyAnnals of Oncology, 1999
- A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalationCancer Chemotherapy and Pharmacology, 1999
- Activity of the multitargeted antifolate LY231514 in the human tumor cloning assayCancer Chemotherapy and Pharmacology, 1999
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II StudyJournal of Clinical Oncology, 1999
- Review on evidence-based cancer medicineAnnals of Oncology, 1998
- Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)Advances in Enzyme Regulation, 1998
- Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasisCancer Chemotherapy and Pharmacology, 1997
- A dideazatetrahydrofolate analog lacking a chiral center at C-6: N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-L-glutamic acid is an inhibitor of thymidylate synthaseJournal of Medicinal Chemistry, 1992